£520.00

The 2023-2028 Outlook for Prostaglandin Glaucoma Therapeutics in the United States

Subjects

Price data checked 5 days ago

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£520 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 86 days · 86 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 86 days • 1 price levels

Days at Price

Price Analysis

Most common price: £520 (86 days, 100.0%)

Price range: £520 - £520

Price levels: 1 different prices over 86 days

Description

This study covers the latent demand outlook for prostaglandin glaucoma therapeutics across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each city in question, the percent share the city is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for prostaglandin glaucoma therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of prostaglandin glaucoma therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Aerie Pharmaceuticals, Allergan, Merck & Company, Novartis, Pfizer, Santen Pharmaceutical Company, and Valeant Pharmaceuticals International. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BLQYMQHN
Category: Books > Subjects
Domain: Amazon UK
Release Date: 26 October 2022
Listed Since: 10 November 2022

The 2023-2028 Outlook for Prostaglandin Glaucoma Therapeutics in the United States

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Prostaglandin Glaucoma Therapeutics in India

The 2023-2028 Outlook for Prostaglandin Glaucoma Therapeutics in Japan

The 2023-2028 Outlook for Prostaglandin Glaucoma Therapeutics for US Zip Codes

The 2025-2030 World Outlook for Glaucoma Pharmaceuticals

The 2023-2028 Outlook for Anti-Vascular Endothelial Growth Factor Therapy (Anti-VEGF) for Non-Infectious Macular Edema in the United States

The 2023-2028 Outlook for Macular Degeneration Treatments in the United States

The 2023-2028 Outlook for Macular Degeneration Treatments in India

The 2023-2028 Outlook for Vision Care in India

The 2023-2028 Outlook for Proliferative Diabetic Retinopathy Treatments in the United States

The 2023-2028 Outlook for Myopia and Presbyopia Treatments in India

The 2016-2021 Outlook for Prescription Eyeglass Frames in Greater China

The 2023-2028 Outlook for Uveitis Drugs in India

The 2023-2028 Outlook for Eye Drops in India

Glaucoma

The 2023-2028 Outlook for Optical Goods and Eye Care Products in the United States

The 2027-2032 World Outlook for Eye Drops

The 2016-2021 Outlook for Prescription Eyeglasses in India

Surgical Management of Childhood Glaucoma: Clinical Considerations and Techniques

The 2023-2028 Outlook for Reading Glasses in the United States

The 2023-2028 Outlook for Prescription Safety Glasses in India

Symposium on Medical Therapy in Glaucoma, Amsterdam, May 15, 1976: 12 (Documenta Ophthalmologica Proceedings Series, 12)

Pearls of Glaucoma Management

The 2023-2028 Outlook for Ophthalmic Anti-Inflammatory Pharmaceutical Drugs in the United States

The 2016-2021 Outlook for Prescription Eyeglasses in Greater China